Menu Search
Equities

Siegfried Holding AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0QQO:LSE

Siegfried Holding AG

Actions
  • Price (CHF)89.39
  • Today's Change-1.77 / -1.94%
  • Shares traded17.55k
  • 1 Year change-15.83%
  • Beta0.7294
Data delayed at least 20 minutes, as of Feb 16 2026 17:39 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.

  • Revenue in CHF (TTM)1.29bn
  • Net income in CHF154.39m
  • Incorporated1904
  • Employees3.93k
  • Location
    Siegfried Holding AGUntere Bruehlstrasse 4ZOFINGEN 4800SwitzerlandCHE
  • Phone+41 627461111
  • Fax+41 627461202
  • Websitehttps://www.siegfried.ch/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SFZN:SWX since
announced		Transaction
value
Noramco Inc,Purisys LLCAnnounced27 Jan 202627 Jan 2026Announced1.48%--
Tasmanian Alkaloids Pty LtdAnnounced27 Jan 202627 Jan 2026Announced1.48%--
Data delayed at least 15 minutes, as of Feb 16 2026 16:31 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.